Loading…
The Clinical Frailty Scale as useful tool in patients with brain metastases
Purpose The Clinical Frailty Scale (CFS) evaluates patients’ level of frailty on a scale from 1 to 9 and is commonly used in geriatric medicine, intensive care and orthopedics. The aim of our study was to reveal whether the CFS allows a reliable prediction of overall survival (OS) in patients after...
Saved in:
| Published in: | Journal of neuro-oncology 2022-05, Vol.158 (1), p.51-57 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3 |
| container_end_page | 57 |
| container_issue | 1 |
| container_start_page | 51 |
| container_title | Journal of neuro-oncology |
| container_volume | 158 |
| creator | Kerschbaumer, Johannes Krigers, Aleksandrs Demetz, Matthias Pinggera, Daniel Klingenschmid, Julia Pichler, Nadine Thomé, Claudius Freyschlag, Christian F. |
| description | Purpose
The Clinical Frailty Scale (CFS) evaluates patients’ level of frailty on a scale from 1 to 9 and is commonly used in geriatric medicine, intensive care and orthopedics. The aim of our study was to reveal whether the CFS allows a reliable prediction of overall survival (OS) in patients after surgical treatment of brain metastases (BM) compared to the Karnofsky Performance Score (KPS).
Methods
Patients operated for BM were included. CFS and KPS were retrospectively assessed pre- and postoperatively and at follow-up 3–6 months after resection.
Results
205 patients with a follow-up of 22.8 months (95% CI 18.4–27.1) were evaluated. CFS showed a median of 3 (“managing well”; IqR 2–4) at all 3 assessment-points. Median KPS was 80 preoperatively (IqR 80–90) and 90 postoperatively (IqR 80–100) as well as at follow-up after 3–6 months. CFS correlated with KPS both preoperatively (r = − 0.92; p |
| doi_str_mv | 10.1007/s11060-022-04008-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9166853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2650254995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3</originalsourceid><addsrcrecordid>eNp9kU9LHEEQxRuJ6Gr8AjmEhlxyGa3-33MJhEVNUPCgQm5Nz2yN29I7s-meUfz2aV01mkOgoWjqV69e8Qj5xOCQAZijzBhoqIDzCiSArdQWmTFlRGWEER_IDJg2larlr12yl_MtAEgj2A7ZFUqy2ig-I2dXS6TzGPrQ-khPkg9xfKCX5YPUZzpl7KZIx2GINPR07ceA_ZjpfRiXtCl0T1c4-lwe5o9ku_Mx48Fz3SfXJ8dX8x_V-cXpz_n386qVIMeKC2YBRA1KopLCG40AnWm0bXWjgbOaLRambXjXFZdKMzRgUXHbCG0XshP75NtGdz01K1y0xVHy0a1TWPn04AYf3PtOH5buZrhzNdPaKlEEvj4LpOH3hHl0q5BbjNH3OEzZca2AK1nXqqBf_kFvhyn15bxCGW6lqKUtFN9QbRpyTti9mmHgHrNym6xcyco9ZeUepT-_PeN15CWcAogNkEurv8H0d_d_ZP8AsDeeNg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2672843948</pqid></control><display><type>article</type><title>The Clinical Frailty Scale as useful tool in patients with brain metastases</title><source>Springer Link</source><creator>Kerschbaumer, Johannes ; Krigers, Aleksandrs ; Demetz, Matthias ; Pinggera, Daniel ; Klingenschmid, Julia ; Pichler, Nadine ; Thomé, Claudius ; Freyschlag, Christian F.</creator><creatorcontrib>Kerschbaumer, Johannes ; Krigers, Aleksandrs ; Demetz, Matthias ; Pinggera, Daniel ; Klingenschmid, Julia ; Pichler, Nadine ; Thomé, Claudius ; Freyschlag, Christian F.</creatorcontrib><description><![CDATA[Purpose
The Clinical Frailty Scale (CFS) evaluates patients’ level of frailty on a scale from 1 to 9 and is commonly used in geriatric medicine, intensive care and orthopedics. The aim of our study was to reveal whether the CFS allows a reliable prediction of overall survival (OS) in patients after surgical treatment of brain metastases (BM) compared to the Karnofsky Performance Score (KPS).
Methods
Patients operated for BM were included. CFS and KPS were retrospectively assessed pre- and postoperatively and at follow-up 3–6 months after resection.
Results
205 patients with a follow-up of 22.8 months (95% CI 18.4–27.1) were evaluated. CFS showed a median of 3 (“managing well”; IqR 2–4) at all 3 assessment-points. Median KPS was 80 preoperatively (IqR 80–90) and 90 postoperatively (IqR 80–100) as well as at follow-up after 3–6 months. CFS correlated with KPS both preoperatively (r = − 0.92; p < 0.001), postoperatively (r = − 0.85; p < 0.001) and at follow-up (r = − 0.93; p < 0.001).
The CFS predicted the expected reduction of OS more reliably than the KPS at all 3 assessments. A one-point increase (worsening) of the preoperative CFS translated into a 30% additional hazard to decease (HR 1.30, 95% CI 1.15–1.46; p < 0.001). A one-point increase in postoperative and at follow-up CFS represents a 39% (HR 1.39, 95% CI 1.25–1.54; p < 0.001) and of 42% risk (HR 1.42, 95% CI 1.27–1.59; p < 0.001).
Conclusion
The CFS is a feasible, simple and reliable scoring system in patients undergoing resection of brain metastasis. The CFS 3–6 months after surgery specifies the expected OS more accurately than the KPS.]]></description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-022-04008-5</identifier><identifier>PMID: 35419752</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Brain cancer ; Brain Neoplasms - surgery ; Frailty ; Frailty - diagnosis ; Humans ; Karnofsky Performance Status ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Neurology ; Oncology ; Patients ; Retrospective Studies</subject><ispartof>Journal of neuro-oncology, 2022-05, Vol.158 (1), p.51-57</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3</citedby><cites>FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35419752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kerschbaumer, Johannes</creatorcontrib><creatorcontrib>Krigers, Aleksandrs</creatorcontrib><creatorcontrib>Demetz, Matthias</creatorcontrib><creatorcontrib>Pinggera, Daniel</creatorcontrib><creatorcontrib>Klingenschmid, Julia</creatorcontrib><creatorcontrib>Pichler, Nadine</creatorcontrib><creatorcontrib>Thomé, Claudius</creatorcontrib><creatorcontrib>Freyschlag, Christian F.</creatorcontrib><title>The Clinical Frailty Scale as useful tool in patients with brain metastases</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description><![CDATA[Purpose
The Clinical Frailty Scale (CFS) evaluates patients’ level of frailty on a scale from 1 to 9 and is commonly used in geriatric medicine, intensive care and orthopedics. The aim of our study was to reveal whether the CFS allows a reliable prediction of overall survival (OS) in patients after surgical treatment of brain metastases (BM) compared to the Karnofsky Performance Score (KPS).
Methods
Patients operated for BM were included. CFS and KPS were retrospectively assessed pre- and postoperatively and at follow-up 3–6 months after resection.
Results
205 patients with a follow-up of 22.8 months (95% CI 18.4–27.1) were evaluated. CFS showed a median of 3 (“managing well”; IqR 2–4) at all 3 assessment-points. Median KPS was 80 preoperatively (IqR 80–90) and 90 postoperatively (IqR 80–100) as well as at follow-up after 3–6 months. CFS correlated with KPS both preoperatively (r = − 0.92; p < 0.001), postoperatively (r = − 0.85; p < 0.001) and at follow-up (r = − 0.93; p < 0.001).
The CFS predicted the expected reduction of OS more reliably than the KPS at all 3 assessments. A one-point increase (worsening) of the preoperative CFS translated into a 30% additional hazard to decease (HR 1.30, 95% CI 1.15–1.46; p < 0.001). A one-point increase in postoperative and at follow-up CFS represents a 39% (HR 1.39, 95% CI 1.25–1.54; p < 0.001) and of 42% risk (HR 1.42, 95% CI 1.27–1.59; p < 0.001).
Conclusion
The CFS is a feasible, simple and reliable scoring system in patients undergoing resection of brain metastasis. The CFS 3–6 months after surgery specifies the expected OS more accurately than the KPS.]]></description><subject>Aged</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - surgery</subject><subject>Frailty</subject><subject>Frailty - diagnosis</subject><subject>Humans</subject><subject>Karnofsky Performance Status</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Retrospective Studies</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kU9LHEEQxRuJ6Gr8AjmEhlxyGa3-33MJhEVNUPCgQm5Nz2yN29I7s-meUfz2aV01mkOgoWjqV69e8Qj5xOCQAZijzBhoqIDzCiSArdQWmTFlRGWEER_IDJg2larlr12yl_MtAEgj2A7ZFUqy2ig-I2dXS6TzGPrQ-khPkg9xfKCX5YPUZzpl7KZIx2GINPR07ceA_ZjpfRiXtCl0T1c4-lwe5o9ku_Mx48Fz3SfXJ8dX8x_V-cXpz_n386qVIMeKC2YBRA1KopLCG40AnWm0bXWjgbOaLRambXjXFZdKMzRgUXHbCG0XshP75NtGdz01K1y0xVHy0a1TWPn04AYf3PtOH5buZrhzNdPaKlEEvj4LpOH3hHl0q5BbjNH3OEzZca2AK1nXqqBf_kFvhyn15bxCGW6lqKUtFN9QbRpyTti9mmHgHrNym6xcyco9ZeUepT-_PeN15CWcAogNkEurv8H0d_d_ZP8AsDeeNg</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Kerschbaumer, Johannes</creator><creator>Krigers, Aleksandrs</creator><creator>Demetz, Matthias</creator><creator>Pinggera, Daniel</creator><creator>Klingenschmid, Julia</creator><creator>Pichler, Nadine</creator><creator>Thomé, Claudius</creator><creator>Freyschlag, Christian F.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202205</creationdate><title>The Clinical Frailty Scale as useful tool in patients with brain metastases</title><author>Kerschbaumer, Johannes ; Krigers, Aleksandrs ; Demetz, Matthias ; Pinggera, Daniel ; Klingenschmid, Julia ; Pichler, Nadine ; Thomé, Claudius ; Freyschlag, Christian F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - surgery</topic><topic>Frailty</topic><topic>Frailty - diagnosis</topic><topic>Humans</topic><topic>Karnofsky Performance Status</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kerschbaumer, Johannes</creatorcontrib><creatorcontrib>Krigers, Aleksandrs</creatorcontrib><creatorcontrib>Demetz, Matthias</creatorcontrib><creatorcontrib>Pinggera, Daniel</creatorcontrib><creatorcontrib>Klingenschmid, Julia</creatorcontrib><creatorcontrib>Pichler, Nadine</creatorcontrib><creatorcontrib>Thomé, Claudius</creatorcontrib><creatorcontrib>Freyschlag, Christian F.</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kerschbaumer, Johannes</au><au>Krigers, Aleksandrs</au><au>Demetz, Matthias</au><au>Pinggera, Daniel</au><au>Klingenschmid, Julia</au><au>Pichler, Nadine</au><au>Thomé, Claudius</au><au>Freyschlag, Christian F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Clinical Frailty Scale as useful tool in patients with brain metastases</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2022-05</date><risdate>2022</risdate><volume>158</volume><issue>1</issue><spage>51</spage><epage>57</epage><pages>51-57</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract><![CDATA[Purpose
The Clinical Frailty Scale (CFS) evaluates patients’ level of frailty on a scale from 1 to 9 and is commonly used in geriatric medicine, intensive care and orthopedics. The aim of our study was to reveal whether the CFS allows a reliable prediction of overall survival (OS) in patients after surgical treatment of brain metastases (BM) compared to the Karnofsky Performance Score (KPS).
Methods
Patients operated for BM were included. CFS and KPS were retrospectively assessed pre- and postoperatively and at follow-up 3–6 months after resection.
Results
205 patients with a follow-up of 22.8 months (95% CI 18.4–27.1) were evaluated. CFS showed a median of 3 (“managing well”; IqR 2–4) at all 3 assessment-points. Median KPS was 80 preoperatively (IqR 80–90) and 90 postoperatively (IqR 80–100) as well as at follow-up after 3–6 months. CFS correlated with KPS both preoperatively (r = − 0.92; p < 0.001), postoperatively (r = − 0.85; p < 0.001) and at follow-up (r = − 0.93; p < 0.001).
The CFS predicted the expected reduction of OS more reliably than the KPS at all 3 assessments. A one-point increase (worsening) of the preoperative CFS translated into a 30% additional hazard to decease (HR 1.30, 95% CI 1.15–1.46; p < 0.001). A one-point increase in postoperative and at follow-up CFS represents a 39% (HR 1.39, 95% CI 1.25–1.54; p < 0.001) and of 42% risk (HR 1.42, 95% CI 1.27–1.59; p < 0.001).
Conclusion
The CFS is a feasible, simple and reliable scoring system in patients undergoing resection of brain metastasis. The CFS 3–6 months after surgery specifies the expected OS more accurately than the KPS.]]></abstract><cop>New York</cop><pub>Springer US</pub><pmid>35419752</pmid><doi>10.1007/s11060-022-04008-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2022-05, Vol.158 (1), p.51-57 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9166853 |
| source | Springer Link |
| subjects | Aged Brain cancer Brain Neoplasms - surgery Frailty Frailty - diagnosis Humans Karnofsky Performance Status Medicine Medicine & Public Health Metastases Metastasis Neurology Oncology Patients Retrospective Studies |
| title | The Clinical Frailty Scale as useful tool in patients with brain metastases |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A26%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Clinical%20Frailty%20Scale%20as%20useful%20tool%20in%20patients%20with%20brain%20metastases&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Kerschbaumer,%20Johannes&rft.date=2022-05&rft.volume=158&rft.issue=1&rft.spage=51&rft.epage=57&rft.pages=51-57&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-022-04008-5&rft_dat=%3Cproquest_pubme%3E2650254995%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-23180039054e543a76e00f7b68c6b602191dd7cb2ff419561e708e528b368d4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2672843948&rft_id=info:pmid/35419752&rfr_iscdi=true |